Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT)
Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
Molecular imaging and quantification of neurological diseases
Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases
Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H(2024) MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy Radiother Oncol, 195, 110263(in press) DOI 10.1016/j.radonc.2024.110263, PubMed 38556173
Tulipan A, Gulati A, Haslerud T, Gray R, Biermann M(2024) Rebooting nuclear medicine specialist education under the COVID-19 pandemic: From plenary lectures to active e-learning Clin Physiol Funct Imaging(in press) DOI 10.1111/cpf.12875, PubMed 38413379
Galtung KF, Lauritzen PM, Rud E(2024) Reply to Fabio Zattoni, Fabrizio Dal Moro, Iliana Bednarova, and Giacomo Novara's Letter to the Editor re: Kristina F. Galtung, Peter M. Lauritzen, Gunnar Sandbæk, et al. Is a Single Nephrographic Phase Computed Tomography Sufficient for Detecting Urothelial Carcinoma in Patients with Visible Haematuria? A Prospective Paired Noninferiority Comparison. Eur Urol Open Sci 2023;55:1-10 Eur Urol Open Sci, 61, 54-55 DOI 10.1016/j.euros.2024.01.014, PubMed 38357532